Therapeutics Company Announce FDA Acceptance For New Galactosemia Treatment
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia: A Revolution in Healthcare.
In a significant development for the healthcare sector and investors worldwide, Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company, has announced the Food and Drug Administration's acceptance and priority review of their New Drug Application (NDA) for Govorestat for the treatment of Classic Galactosemia. Furthermore, the company has declared a $100 million private placement, making it a focal point for both patients and investors. $Applied Therapeutics(APLT.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment